or Try an Advanced Search...

    Technical Analysis for ORIC - Oric Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 8.74 -1.69% -0.15
    ORIC closed down 1.69 percent on Wednesday, November 20, 2024, on 71 percent of normal volume.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical ORIC trend table...
    Date Alert Name Type % Chg
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Wide Bands Range Expansion -1.69%
    Oversold Stochastic Weakness -1.69%
    Stochastic Reached Oversold Weakness 2.10%
    Inside Day Range Contraction 2.10%
    Wide Bands Range Expansion 2.10%
    Oversold Stochastic Weakness 2.10%
    MACD Bearish Centerline Cross Bearish 2.82%
    Older End-of-Day Signals for ORIC ...

       Recent Intraday Alerts

    Alert Time
    Down 3% about 20 hours ago
    Down 2 % about 22 hours ago
    Down 1% about 22 hours ago
    Rose Above Previous Day's High 2 days ago
    Up 3% 2 days ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ORIC Chart by TradingView
    Basic chart:

    Profile

    ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Immunotherapy Cancer Treatment Oncology Treatment Of Cancer Chemotherapy Occupational Safety And Health Antineoplastic Drugs Precision Medicine Specialty Drugs Cancer Therapeutics Cd73

    Is ORIC a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 13 ORIC Pharmaceuticals GAAP EPS of -$0.49 in-line
    Nov 12 ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates
    Nov 4 ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
    Nov 1 ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    Oct 23 ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
    Oct 15 Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth
    Oct 9 ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
    Sep 14 ORIC Pharmaceuticals, Inc. (ORIC): Short Seller Sentiment is Bearish on This Cancer Stock
    Sep 6 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    Sep 6 Stifel starts ORIC at buy, cites prostate cancer drug candidate
    See more ORIC news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 16.63
    52 Week Low 6.33
    Average Volume 485,742
    200-Day Moving Average 10.10
    50-Day Moving Average 9.62
    20-Day Moving Average 9.31
    10-Day Moving Average 9.46
    Average True Range 0.71
    RSI (14) 41.52
    ADX 16.61
    +DI 24.13
    -DI 24.98
    Chandelier Exit (Long, 3 ATRs) 8.97
    Chandelier Exit (Short, 3 ATRs) 10.24
    Upper Bollinger Bands 10.74
    Lower Bollinger Band 7.89
    Percent B (%b) 0.3
    BandWidth 30.64
    MACD Line -0.15
    MACD Signal Line -0.03
    MACD Histogram -0.1133
    Fundamentals Value
    Market Cap 586.03 Million
    Num Shares 67.1 Million
    EPS -1.98
    Price-to-Earnings (P/E) Ratio -4.41
    Price-to-Sales 0.00
    Price-to-Book 3.43
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 9.30
    Resistance 3 (R3) 9.27 9.06 9.20
    Resistance 2 (R2) 9.06 8.92 9.07 9.17
    Resistance 1 (R1) 8.90 8.83 8.80 8.93 9.14
    Pivot Point 8.69 8.69 8.64 8.70 8.69
    Support 1 (S1) 8.53 8.55 8.43 8.56 8.34
    Support 2 (S2) 8.32 8.46 8.33 8.31
    Support 3 (S3) 8.16 8.32 8.28
    Support 4 (S4) 8.19